Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature.
about
Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosisAdvances in the management of myelofibrosisThe evolving treatment paradigm in myelofibrosisNovel therapies for myelofibrosisPractical management of classical myeloproliferative disorder patients: a clinician's guideModern management of myelofibrosis.Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results.Alleviating anemia and thrombocytopenia in myelofibrosis patients.Managing patients with myelofibrosis and low platelet counts.A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosisRed blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.Choosing between stem cell therapy and drugs in myelofibrosis.How to manage the transplant question in myelofibrosis.Allogeneic stem cell transplantation as treatment for myelofibrosis.Myelofibrosis: biology and treatment options.Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependenceTherapeutic approaches in myelofibrosis.Myelofibrosis: an update on current pharmacotherapy and future directions.Treatment and management of myelofibrosis in the era of JAK inhibitorsTargeting hedgehog signaling in myelofibrosis and other hematologic malignanciesMyelofibrosis: an update on drug therapy in 2016.Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis.Primary myelofibrosis: current therapeutic options.Emerging therapeutic options for myelofibrosis: a Canadian perspective.Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients.Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response.Guideline for the diagnosis and management of myelofibrosis.Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis.A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.Responses to pomalidomide and placebo in myelofibrosis-related anaemia.How to manage polycythemia vera.Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.
P2860
Q26770330-54211881-A926-49CC-B59F-DC9E76BAF05CQ27008072-D51FE076-D44E-479D-8110-FC048407F540Q27021968-8B8499CE-CE42-4394-A6FC-C3DDF88DC370Q28081693-E46D8065-772D-4412-A558-6BF0257D9193Q28200207-9B78449D-B035-4F59-9004-AD40FAB4B01AQ33365122-FAF7EB4D-248E-4D2D-BEAC-24CC3D11CC16Q33423956-9966E116-225B-49B4-BCE6-2885355B1274Q33430113-0A1BF955-28BA-49D8-9CFF-67E56BA49CBBQ33432406-DBF7E1AC-4B56-493C-B3A7-F71488160EF2Q33434284-BCEDAD80-5CA1-4416-A20B-C0FCCED2BCA7Q34451630-D9C52655-8538-4279-9624-C4776191C468Q34625390-E5844D94-E660-40D6-B12E-FD0C00047EF8Q34734491-9F73C8B7-4779-420F-A9DA-08723700B223Q35865676-B0EA367E-D7DF-476A-BAD2-2B1F32ABE804Q36609417-58AEF56D-85C4-4363-B26D-FB22D1C14412Q36922494-4E4686ED-9240-4AEA-8894-7048BBC2F097Q37163590-4EA4A1DC-5FC5-46F2-843B-5CA161782C4DQ37529843-C9C26EED-65FC-4F19-A7E5-EEEABBC20981Q37740928-12C318E4-632A-4122-860F-AC2421E395F3Q37860336-9F1E10B9-70A7-4A53-8921-2FCFE29FDE12Q38091447-439E7F5C-4B44-4344-A431-62182ECB6B7BQ38132739-84611A52-BD3A-4A39-88D7-BBED82660E41Q38193610-B8E084A0-2B9C-4F11-86E1-AF511E8AC761Q38989215-5EF0F877-7253-4554-8EB9-B70F3ECC0AFCQ39069010-1101F486-98CA-498A-8072-B01282AF9237Q41186952-EB605515-2CF3-4636-BE71-3547FD6B31C1Q41627599-5D8EA90E-DE92-4C06-A568-32F3954642F0Q42201127-4E8FBF51-19B9-4EB7-BDEB-CFF62F464582Q46543499-33B047EE-0F66-4214-AA92-DBEDEC850BBCQ50042813-6500215C-8966-4C40-A6DC-A0E28946A67CQ50495964-65E4175B-F1FF-43CC-9E61-199A00815B72Q50712240-959FA675-0804-486F-B255-53744CC77A74Q51111145-FBF93693-257F-4354-9829-C009A9D66182Q54540928-0353A254-78C8-44A8-905B-E2232D14D8A5Q54544165-1332695E-BD5D-49D2-A442-59132ACD28F7Q54573577-91B74F60-6756-4205-961D-5DF8597A6D1B
P2860
Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Erythropoietin treatment of th ...... and review of the literature.
@ast
Erythropoietin treatment of th ...... and review of the literature.
@en
type
label
Erythropoietin treatment of th ...... and review of the literature.
@ast
Erythropoietin treatment of th ...... and review of the literature.
@en
prefLabel
Erythropoietin treatment of th ...... and review of the literature.
@ast
Erythropoietin treatment of th ...... and review of the literature.
@en
P2093
P2860
P1476
Erythropoietin treatment of th ...... s and review of the literature
@en
P2093
Alberto Alvarez-Larrán
Ana Sureda
Emili Montserrat
Francisco Cervantes
Montserrat Torrebadell
P2860
P304
P356
10.1111/J.1365-2141.2004.05229.X
P407
P577
2004-11-01T00:00:00Z